Friday, July 10, 2026

pharma · Primary Brain Tumor · Hepatocellular Carcinoma

Guerbet

Guerbet is a pharma organization headquartered in VILLEPINTE, FR. Primary therapeutic focus areas include Primary Brain Tumor, Hepatocellular Carcinoma, Motor Function. NovaPharmaNews links 4 clinical program(s), 0 drug

VILLEPINTE, FR HQ
1926 Founded
2,465 Employees
EMA registrant Type
Company details
Status
Public
HQ
VILLEPINTE, FR
Founded
1926
Employees
2,465
Programs
4
Drugs
5
Patents
0
Clinical program

Dotarem®

Approved · small molecule · Primary Brain Tumor

Dotarem® for Primary Brain Tumor is a Approved program (small_molecule) at Guerbet with 1 ClinicalTrials.gov record(s).

← All Guerbet projects Approved small molecule completed

Internal code DGD-44-058

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Guerbet
Phase
Approved
Modality
small_molecule
Indication
Primary Brain Tumor
Status
completed
Trials
1